Claims
- 1. An IL-18 mutant polypeptide, comprising mutations in one or more amino acid residues which are involved in its interaction with IL-18 binding protein.
- 2. The polypeptide according to claim 1, wherein the mutations are substitutions, additions or deletions.
- 3. The polypeptide according to claim 2, wherein the substitutions are non-conservative.
- 4. The polypeptide according to anyone of claims 1, 2 or 3, wherein the mutation is in a residue selected from a group consisting of Glu-42, Ile-85, Met-87, Lys-89, Met-96, Asp-130, Lys-132, Pro-143, Met-149, and Leu-189.
- 5. The polypeptide according to claim 4, wherein the mutation is in a residue selected from the group consisting of Glu-42 and Lys-89.
- 6. The polypeptide according to claim 5, wherein the mutation is in a Glu-42 residue.
- 7. The polypeptide according to claim 5, wherein the mutation is in a Lys-89 residue.
- 8. The polypeptide according to claim 5, wherein the mutation is in a Glu-42 residue and a Lys-89 residue.
- 9. The polypeptide according to claim 6, wherein the Glu-42 residue is replaced with a non-polar amino acid.
- 10. The polypeptide according to claim 9, wherein the Glu-42 is replaced with an Ala residue.
- 11. The polypeptide according to claim 7, wherein the Lys-89 residue is replaced with a non-polar amino acid.
- 12. The polypeptide according to claim 11, wherein the Lys-89 is replaced with an Ala residue.
- 13. The polypeptide according to claim 8, wherein both the Glu-42 residue and the Lys-89 residues are replaced with a non-polar amino acid.
- 14. The polypeptide according to claim 13, where both the Glu-42 and the Lys-89 residues are replaced with an Ala residue.
- 15. An isolated DNA encoding a polypeptide according to claim 1.
- 16. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of SEQ ID NO:3.
- 17. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of encoding the polypeptide of SEQ ID NO:4.
- 18. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of encoding the polypeptide of SEQ ID NO:5.
- 19. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of encoding the polypeptide of SEQ ID NO:6.
- 20. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of encoding the polypeptide of SEQ ID NO:7.
- 21. The DNA according to claim 15, wherein the polypeptide has amino acid sequence of encoding the polypeptide of SEQ ID NO:8.
- 22. The DNA according to claim 15 further comprising a nucleic acid sequence encoding a signal peptide.
- 23. The DNA according to claim 22, wherein the signal peptide is that of a growth hormone.
- 24. A vector comprising a DNA according to claim 15, wherein said vector is capable of expressing the polypeptide encoded by said DNA in an appropriate host cell.
- 25. The vector according to claim 24, wherein the host cell is prokaryotic.
- 26. The vector according to claim 25, wherein the DNA encodes a polypeptide selected from a group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
- 27. The vector according to claim 24, wherein the host cell is an eukaryotic cell.
- 28. The vector according to claim 27, wherein the DNA encodes a polypeptide selected from a group consisting of SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.
- 29. The vector according to claim 27, comprising DNA according to claim 22 or 23.
- 30. The vector according to claim 28, wherein said DNA is ligated to the sequence encoding the human growth hormone signal peptide.
- 31. A pharmaceutical composition comprising a polypeptide according to claims 1 and a pharmaceutically acceptable carrier.
- 32. A method of treating a disease which is prevented or alleviated by a Th1 response, comprising administering a pharmaceutical composition of claim 31 to an individual in need thereof.
- 33. The method according to claim 32, wherein the disease is cancer.
- 34. The method according to claim 32, wherein the disease is a viral disease.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/274,327, filed Mar. 8, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60274327 |
Mar 2001 |
US |